B. Freilich

机构：University of Chicago, Kansas City Research Institute

发表论文 59 篇 · 总被引 4767 次 · h-index 23

代表论文

• Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial (2019 · The Lancet · 被引 1244)
• Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials (2020 · Journal of Hepatology · 被引 486)
• Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial (2021 · Nature Medicine · 被引 357)
• Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial (2020 · Hepatology · 被引 333)
• Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study (2017 · ˜The œLancet. Gastroenterology & hepatology · 被引 188)
• CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients (2019 · Liver International · 被引 160)